Postinflammatory hyperpigmentation
Postinflammatory hyperpigmentation wani yanayi ne na fata wanda ke da yawan launin launi a cikin fata bayan kumburin fata. Postinflammatory hyperpigmentation na iya haifar da shi ta hanyar tsawaita fitowar rana, kumburi, ko wasu raunin fata, gami da masu alaƙa da kuraje. Mutane masu launin fata masu duhu yawanci sun fi dacewa da hyperpigmentation tare da wuce haddi na rana.
☆ A cikin sakamakon Stiftung Warentest na 2022 daga Jamus, gamsuwar mabukaci tare da ModelDerm ya ɗan yi ƙasa kaɗan fiye da biyan shawarwarin telemedicine.
References
Postinflammatory hyperpigmentation (PIH) shine matsalar fata da ake yawan samu bayan kumburin fata ko rauni. Yakan dade yana dadewa kuma ya fi muni a cikin mutane masu launin fata (Fitzpatrick skin types III–VI) . Ko da yake sau da yawa yana samun sauki da kansa, wannan na iya ɗaukar ɗan lokaci, don haka sau da yawa ana buƙatar magani na dogon lokaci. Haɗa jiyya daban-daban yana aiki mafi kyau.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation shi ne na yau da kullun na kumburin fata. Yana yin tasiri ga mutane masu launin fata mai tsanani da kuma akai-akai. Nazarin ya nuna cewa batutuwa kamar postinflammatory hyperpigmentation suna daga cikin manyan dalilan da ke sa mutane masu launin fata suna neman kulawar fata. Magani na farko yana da mahimmanci don warware postinflammatory hyperpigmentation kuma yawanci yana farawa da sarrafa yanayin kumburin farko. Layin farko na jiyya yawanci ya haɗa da yin amfani da magunguna masu haske waɗanda ke haskaka fata tare da hasken rana don kariya. Waɗannan wakilai, kamar hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , suna iya rage yawan pigment yadda ya kamata. Bugu da ƙari, retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy kuma ana amfani da su azaman wakilai masu lalata launi, tare da sabbin jiyya da ke fitowa. Duk da yake jiyya na cikin gida galibi suna da tasiri ga matakin-hyperpigmentation, hanyoyin (laser, chemical peel) na iya zama dole don lokuta masu taurin kai. Yana da mahimmanci a yi amfani da taka tsantsan tare da waɗannan jiyya don guje wa fushi da muni na postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
